News

Medical Dialogues1h
Thyroid Cancer Red Flag: FDA Adverse Reporting Data Analysis Shows Alerts on Semaglutide, Tirzepatide Use
Lebanon: A recent study analyzing data from the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) has ...
Shedding weight may no longer be a prickly issue as Eli Lilly’s weight-loss pill moves closer to launch
Eli Lilly's new oral weight-loss pill, orforglipron, shows promise in late-stage trials across countries like India and the US. Participants experienced an average weight loss of 7.2 kg with the 36 mg ...
Medicare Executive Order Boosts Drug Industry’s Profits as Seniors Suffer: Report
The Medicare Rights Center reports that President Trump’s executive order on prescription drug pricing supports key drug ...
Shedding weight without the jab: Eli Lilly’s weight-loss pill moves closer to launch
Eli Lilly's new oral weight-loss pill, orforglipron, shows promise in late-stage trials across countries like India and the ...
Verywell Health13h
Daily GLP-1 Pill Shows Promise for Diabetes and Weight Loss, Eli Lilly Says
A new drug, called orforglipron, can help people with diabetes manage their A1C and weight, according to topline results from ...
Endocrinologists decode the findings of a new trial and how it widens therapy options
When it comes to oral semaglutide, the OASIS-1 trial showed that it led to a 15.1% reduction in body weight. But this was at ...
Murray Ledger & Times23h
Kentucky doctor admits providing non-approved drug to weight-loss patients
A Kentucky doctor faces up to three years in prison after admitting he sold patients a non-approved weight-loss drug.